Loading organizations...
Key people at Affinity Asset Advisors.
Affinity Asset Advisors operates as a specialized hedge fund, concentrating investments within the dynamic healthcare sector. The firm employs a sophisticated long-short equity strategy, actively identifying and capitalizing on public and private opportunities. Their analytical approach emphasizes uncovering paradigm-shifting innovations, aiming to generate returns through deep sector-specific expertise and active management in the healthcare landscape.
The company was founded in 2017 by Michael Cho and Jonathan Chu. Michael Cho serves as Portfolio Manager, overseeing the firm’s strategic direction and investment decisions. Their founding insight stemmed from recognizing the profound, transformative potential within the healthcare industry, prompting the creation of a dedicated vehicle to rigorously pursue high-impact opportunities.
Affinity Asset Advisors primarily advises sophisticated institutional and high-net-worth clients seeking specialized exposure to healthcare innovation. The firm's long-term vision centers on continuously identifying and supporting groundbreaking developments across biotechnology, pharmaceuticals, and medical technology, aiming to benefit from global healthcare's ongoing evolution.
Key people at Affinity Asset Advisors.
Affinity Asset Advisors has 2 tracked investments across 2 companies. The latest tracked deal is $210.0M Series D in Odyssey Therapeutics in September 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2025 | Odyssey Therapeutics | $210.0M Series D | — | Dimension Capital, General Catalyst, OrbiMed, SR ONE, Third Rock Ventures, Rafaèle Tordjman, Shelley CHU, Paulina Hill, Carolyn NG, Wedbush Healthcare Partners |
| May 1, 2021 | Hummingbird Bioscience | $130.0M Series C | KEN Harrison | Frazier Healthcare Partners, Ally Bridge Group, Altrium Capital Management, Amgen Ventures, Droia Ventures, EDBI, Heritas Capital, Mirae Asset, Morningside Ventures, Octagon Capital, Polaris Partners, Pureos Bioventures, Kiel KIM |